Stay updated with breaking news from Nasdaq Mack. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock. Merrimack Pharmaceuticals Trading Up 1.5 % NASDAQ MACK traded up $0.18 on Thursday, hitting $12.19. 26,084 shares of the company’s stock traded hands, […]
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) insider Gary L. Crocker purchased 2,000 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was bought at an average cost of $12.52 per share, with a total value of $25,040.00. Following the purchase, the insider now owns 133,105 shares in the […]
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK – Get Free Report) Director Eric Andersen acquired 134,493 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were acquired at an average cost of $12.00 per share, for a total transaction of $1,613,916.00. Following the purchase, the director now directly owns 1,496,680 shares […]
Merrimack Pharmaceuticals (NASDAQ:MACK – Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report released on Friday. Merrimack Pharmaceuticals Price Performance Shares of MACK stock traded down $0.08 during trading hours on Friday, reaching $11.80. 209,960 shares of the stock were exchanged, compared to its average volume of […]
Merrimack Pharmaceuticals (NASDAQ:MACK – Get Rating) and Rallybio (NASDAQ:RLYB – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation. Volatility & Risk Merrimack Pharmaceuticals has a beta of 1.84, […]